IntraPace Plans Anti-Obesity Stomach Stimulator Pivotal Trial
This article was originally published in The Gray Sheet
Executive Summary
IntraPace is in discussions with FDA about an investigational device exemption for its abiliti anti-obesity stomach pacemaker system, and hopes to begin a U.S. pivotal trial by early 2012, according to the company.